NIH Schedules Secret Virtual Meetings for Research Grant Reviews
Published Date: 3/5/2026
Notice
Summary
The NIH’s Center for Scientific Review is holding several closed virtual meetings in early April 2026 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide which science projects get funding. Researchers applying for grants in health fields like cancer, heart, and diabetes should note these key review dates.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
NIH grant reviews set for April 7–10
If you applied for NIH research grants in the listed topics, your applications will be reviewed and evaluated in closed panels on April 7–10, 2026. Specific panels include reviews for vector-borne diseases and co-infection and cancer (April 7), cardiovascular and respiratory diseases (April 7–8), diabetes and metabolism (April 8), basic cancer immunobiology (April 8–9), drug and biologic disposition and toxicity (April 9–10), psychopathology (April 9), immunity and host defense (April 9–10), nutrition/diet/obesity/diabetes behavioral interventions (April 9–10), and the RFA-OD-24-011 R50 award panel (April 9).
Applicant trade secrets and privacy protected
The meetings will be closed under 5 U.S.C. 552b(c)(4) and 552b(c)(6) to protect confidential trade secrets, patentable material, and personal information associated with grant applications during the April 7–10, 2026 reviews. If your application includes proprietary data or personal identifiers, those materials are explicitly protected from public disclosure during these reviews.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2026-04336, Sunshine Act Meetings
The Nuclear Regulatory Commission (NRC) is holding an open public meeting via webcast on March 4, 2026, to decide on a key hearing about the Kemmerer Power Station. This quick decision was approved with less than a week’s notice, showing the NRC’s commitment to transparency and timely action. Anyone interested can watch live online, and the NRC offers accommodations to make sure everyone can join in.
Next: 2026-04326, National Cancer Institute; Amended Notice of Meeting
The National Cancer Institute changed the meeting times for March 17, 2026. The open session now starts an hour later and ends an hour earlier, while the closed session also shifts earlier. This update affects anyone planning to attend or follow the National Cancer Advisory Board meeting, with no changes to March 16 or budget impacts.